Oragenics Shares Are Trading Higher After the Company Announced the Filing Completion for Its ONP-002 Drug in Anticipation of Its Phase IIa Clinical Trail in Concussed Patients.
Oragenics Shares Are Trading Higher After the Company Announced the Filing Completion for Its ONP-002 Drug in Anticipation of Its Phase IIa Clinical Trail in Concussed Patients.
Oragenics股票在公司宣佈完成ONP-002藥物的申報後交易上漲，以期望在受傷患者中進行第IIa期臨床試驗。
Oragenics Shares Are Trading Higher After the Company Announced the Filing Completion for Its ONP-002 Drug in Anticipation of Its Phase IIa Clinical Trail in Concussed Patients.
oragenics股票交易走高，公司宣佈完成ONP-002藥物的申報，預計在腦震盪患者的IIa期臨床試驗中進行。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間